Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | HRH2 | P25021 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 6/20 | 0.38 |
| ▸ | ITGAV | P06756 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6852144 | 0.76 | ITGB3 (0.49) | MEN1KMT2AITGB3ITGAVALDH1A1 | |
| SCHEMBL4139801 | 0.68 | KDM4E (0.60) | ALDH1A1MAPTSMN1; SMN2ROCK2ROCK1 | |
| SCHEMBL6852102 | 0.66 | THRB (0.51) | MEN1KMT2AITGB3ITGAVALDH1A1 | |
| SCHEMBL7310808 | 0.65 | MEN1 (0.49) | MEN1KMT2AHRH2HRH1ALDH1A1 | |
| SCHEMBL16167659 | 0.65 | ITGB3 (0.50) | MEN1KMT2AITGB3ITGAVALDH1A1 | |
| SCHEMBL6857392 | 0.64 | THRB (0.52) | MEN1KMT2AITGB3ITGAVALDH1A1 | |
| SCHEMBL20365512 | 0.64 | MEN1 (0.46) | MEN1KMT2AHRH2HRH1ALDH1A1 | |
| SCHEMBL31465622 | 0.64 | MEN1 (0.48) | MEN1KMT2AHRH2HRH1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL28437307 | 0.64 | MEN1 (0.48) | MEN1KMT2AHRH2HRH1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL7500429 | 0.63 | MAPT (0.53) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11351137-B2 | Composition and method for dual targeting in treatment of neuroendocrine tumors | NANOPHARMACEUTICALS LLC (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210299262-A1 | COMPOSITION AND METHOD FOR DUAL TARGETING IN TREATMENT OF NEUROENDOCRINE TUMORS | NANOPHARMACEUTICALS LLC | 2021-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11351137-B2 | Composition and method for dual targeting in treatment of neuroendocrine tumors | THRB, TSHR, SLC6A2 | MEN1 100/4885KMT2A 3019/4885HRH2 1516/4885 |
| US-20210299262-A1 | COMPOSITION AND METHOD FOR DUAL TARGETING IN TREATMENT OF NEUROENDOCRINE TUMORS | THRB, TSHR, SLC6A2 | MEN1 100/4885KMT2A 3019/4885HRH2 1516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.